论文部分内容阅读
为了探索头孢哌酮－舒巴坦（舒普深）对医院感染菌的体外抗菌活性及其临床抗感染的有效性及安全性，对１９９５年度临床标本分离的１３７２株细菌作了包括本药在内的１７种抗生素的敏感性测定，其中革兰阴性菌１０３５株，占７５．４％，革兰阳性菌３３７株，占２４．６％；并应用舒普深治疗以呼吸系为主的细菌感染５０例次。该５０例次（４３例）细菌感染中，５８．０％发生在血液系恶性疾患和实体瘤患者，而０．２４％的患者感染处于粒细胞缺乏状态。细菌培养阳性率５６％。给药方法：每次１．０～２．０ｇ，每日２次，疗程５～１８天，其中＞７天者占５６．０％（２８／５０例次）。结果显示舒普深在体外药敏试验中对常见革兰阴性和阳性菌的敏感率高，耐药率低，优于其他第三代头孢菌素。临床应用中抗感染的有效率为８４．０％（４２／５０例次），细菌清除率为８９．３％（２５／２８例次）。除３例（６．０％）有丙氨酸转氨酶（ＡＬＴ）短暂增高外，未见其他副作用。
In order to explore the in vitro antibacterial activity of cefoperazone-sulbactam (Shu Pushen) against nosocomial infections and the clinical efficacy and safety of its anti-infection, 1372 strains isolated from clinical specimens in 1995 were enrolled in this study. The results showed that 1035 strains of Gram-negative bacteria accounted for 75.4%, 337 strains of Gram-positive bacteria accounted for 24.6% of the total. Among them, Shu Pu-shen was used to treat respiratory-dominant bacteria Infection 50 cases. Of the 50 (43) bacterial infections, 58.0% occurred in patients with hematologic malignancies and solid tumors, while 0.24% were infected with agranulocytosis. Bacterial culture positive rate of 56%. Methods of administration: 1.0 ~ 2.0g each time, 2 times a day, the course of treatment 5 to 18 days, of which> 7 days accounted for 56.0% (28/50 cases). The results showed that Shuxunshen in vitro susceptibility testing of common Gram-negative and positive bacteria with high sensitivity, low resistance rate, superior to other third-generation cephalosporins. In clinical practice, the effective rate of anti-infection was 84.0% (42/50 cases) and the bacterial clearance rate was 89.3% (25/28 cases). No side effects were seen except for a brief increase in alanine aminotransferase (ALT) in 3 patients (6.0%).